



Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Canceled)
2. (Previously Presented) A method of modulating an activity of Rad in a cell, comprising modulating the level of nm23 in the cell.
3. (Previously Presented) The method of claim 2, wherein the level of nm23 is modulated by administering an nm23 polypeptide to the cell.
4. (Previously Presented) The method of claim 2, wherein the level of nm23 is modulated by administering an nm23 polypeptide-encoding nucleic acid to the cell.
5. (Previously Presented) A method for screening for a test compound that modulates the Rad-nm23 interaction, comprising:
 - (a) providing a Rad polypeptide, an nm23 polypeptide, and a test compound; and
 - (b) detecting an interaction between the Rad polypeptide and the nm23 polypeptide, wherein a difference in the interaction between the Rad polypeptide and the nm23 polypeptide in the presence of the test compound, compared to in the absence of the test compound, is indicative of a compound that modulates the Rad-nm23 interaction.
6. (Previously Presented) The method of claim 5, wherein the Rad polypeptide or the nm23 polypeptide are provided as a purified polypeptide preparation.

7. (Previously Presented) The method of claim 5, wherein the Rad polypeptide and the nm23 polypeptide are provided as purified polypeptide preparations.

8. (Previously Presented) The method of claim 6 or 7, wherein the Rad polypeptide, nm23 polypeptide, and the test compound are provided in vitro.

9. (Previously Presented) The method of claim 5, wherein the Rad polypeptide or the nm23 polypeptide provided in (a) are expressed in a cell.

10. (Previously Presented) The method of claim 5, wherein the Rad polypeptide and the nm23 polypeptide provided in (a) are expressed in a cell.

11. (Previously Presented) The method of claim 9 or 10, wherein the test compound is contacted with the cell.

12. (Previously Presented) The method of claim 5, wherein detecting the interaction between the Rad polypeptide and the nm23 polypeptide comprises detecting binding of Rad to nm23.

13. (Previously Presented) The method of claim 5, wherein detecting the interaction between the Rad polypeptide and the nm23 polypeptide comprises detecting a modification of Rad or nm23.

14. (Previously Presented) The method of claim 13, wherein the modification is phosphorylation of nm23.

15. (Previously Presented) The method of claim 5, further comprising (c) administering the compound to an animal and optionally (d) evaluating the in vivo effect of the compound on the animal.

16. (Previously Presented) The method of claim 15, wherein evaluating the in vivo effect of the compound comprises evaluating cell growth in the animal.

17. (New) The method of claim 3, wherein the nm23 polypeptide is a fragment of a naturally occurring nm23 protein.

18. (New) The method of claim 17, wherein the fragment is at least 5 amino acids in length.

19. (New) The method of claim 17, wherein the fragment is at least 10 amino acids in length.

20. (New) The method of claim 17, wherein the fragment is at least 20 amino acids in length.

21. (New) The method of claim 17, wherein the fragment is at least 50 amino acids in length.

22. (New) The method of claim 17, wherein the fragment is at least 100 amino acids in length.

23. (New) The method of claim 17, wherein the fragment is at least 150 amino acids in length.

24. (New) The method of claim 3, wherein the nm23 polypeptide has at least 70% amino acid sequence identity with a naturally occurring nm23 amino acid sequence.

25. (New) The method of claim 24, wherein the nm23 polypeptide has at least 80% amino acid sequence identity with a naturally occurring nm23 amino acid sequence.

26. (New) The method of claim 24, wherein the nm23 polypeptide has at least 90% amino acid sequence identity with a naturally occurring nm23 amino acid sequence.

27. (New) The method of claim 24, wherein the nm23 polypeptide has at least 95% amino acid sequence identity with a naturally occurring nm23 amino acid sequence.

28. (New) The method of claim 24, wherein the nm23 polypeptide has at least 96% amino acid sequence identity with a naturally occurring nm23 amino acid sequence.

29. (New) The method of claim 24, wherein the nm23 polypeptide has at least 97% amino acid sequence identity with a naturally occurring nm23 amino acid sequence.

30. (New) The method of claim 24, wherein the nm23 polypeptide has at least 98% amino acid sequence identity with a naturally occurring nm23 amino acid sequence.

31. (New) The method of claim 24, wherein the nm23 polypeptide has at least 99% amino acid sequence identity with a naturally occurring nm23 amino acid sequence.

32. (New) The method of claim 3, wherein the nm23 polypeptide differs in amino acid sequence at up to 5 residues from the corresponding residues in a naturally occurring nm23 amino acid sequence.

33. (New) The method of claim 3, wherein the nm23 polypeptide differs in amino acid sequence at up to 10 residues from the corresponding residues in a naturally occurring nm23 amino acid sequence.

34. (New) The method of claim 3, wherein the nm23 polypeptide differs in amino acid sequence at up to 5% of the residues from a naturally occurring nm23 amino acid sequence.

35. (New) The method of claim 3, wherein the nm23 polypeptide differs in amino acid sequence at up to 10% of the residues from a naturally occurring nm23 amino acid sequence.

36. (New) The method of claim 3, wherein the nm23 polypeptide is an nm23H1 polypeptide.

37. (New) The method of claim 3, wherein the nm23 polypeptide is an nm23H2 polypeptide.